RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Further pharmacological comparison of D-methamphetamine and L-methamphetamine in rats
Abuse-related behavioral and physiological indices
Xue, Z., Siemian, J. N., Zhu, Q., Blough, B. E., & Li, J.-X. (2019). Further pharmacological comparison of D-methamphetamine and L-methamphetamine in rats: Abuse-related behavioral and physiological indices. Behavioural Pharmacology, 30(5), 422-428. https://doi.org/10.1097/FBP.0000000000000453
Previous preclinical research suggests that L-methamphetamine (L-MA) has potential therapeutic utility to treat psychostimulant abuse. This study examined potential abuse-related and adverse physiological effects of D-MA and L-MA alone and in combination in rats, as these effects had not been previously characterized. Potential abuse-related effects were examined in locomotor sensitization and conditioned place preference paradigms. Body temperature was monitored to assess the physiological effects of these drugs or drug combinations. In the locomotor study, D-MA induced locomotor sensitization to both D-MA and L-MA. L-MA induced locomotor sensitization only to D-MA. Responses to a combination of L-MA and D-MA were not differentially affected by L-MA or D-MA conditioning. In the conditioned place preference study, D-MA and L-MA each induced significant place preference. L-MA did not attenuate D-MA-induced place preference. In the body temperature study, D-MA induced hyperthermia and L-MA induced hypothermia. In combination, L-MA did not affect D-MA-induced hyperthermia. These data suggest that L-MA alone produces less abuse-related and adverse physiological effects than D-MA, but modulates and is modulated by concurrent and subsequent D-MA exposure, which may enhance the abuse liability of both drugs. These findings should be considered when L-MA is proposed for replacement therapy.